Make hope abound.

We are pioneering best-in-class, targeted medicines for severe brain diseases.

We don't follow crowds, chase fads, or pursue me-too drugs.

We leverage non-invasive blood-brain barrier (BBB) delivery technology and mRNA engineering to design and develop life-changing medical products for patients suffering from serious brain diseases. We have active preclinical programs in three areas:

    • GM2 Gangliosidosis (Tay-Sachs & Sandhoff Diseases)
      [Modality: mRNA, Genetic Target: HEXA/HEXB]

    • Lesch-Nyhan Syndrome
      [Modality: mRNA, Genetic Target: HPRT1]

    • Alzheimer's Disease
      [Modality: mRNA, Genetic Target: Undisclosed]

    • GBA1-associated Parkinson's Disease
      [Modality: mRNA, Genetic Target: GBA1]

    • Stroke/TBI
      [Modality: mRNA, Genetic Target: Undisclosed]

To join our mission or learn more about our work, email us at hello@zitra.co.